Immutep Ltd has released a press release.
Immutep achieves Fast Track designation for Efti from US FDA
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Immutep
- Immutep announces European Patent Grant for LAG525
- Immutep collaborates with MSD for phase 2b head & neck trial
- S&P DJI Announces March 2021 Quarterly Rebalance
- Immutep secures second US patent grant for eftilagimod alpha
- Phase II study for eftilagimod alpha in COVID-19 advances
Later from Immutep
- Immutep receives A$1,155,055 R&D Tax Incentive
- TACTI-002 & INSIGHT-004 data to be presented at ASCO
- Operational Update
- Immutep granted Chinese patent for its LAG-3 candidate Efti
- Immutep enters New Collaboration with Merck KGaA for Efti
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep